Finance

Lists
Why is REPL down 2.78%?
Dive Deeper
REPL:NASDAQ
Replimune Group Inc
$12.60
-2.78%
(-0.36) 1D
$12.50
-0.79% (-0.10)
After hours
Closed: Sep 24, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for REPL...
Open
$12.87
High
$12.88
Low
$12.07
Mkt. cap
1.19B
Avg. vol.
2.50M
Volume
2.58M
52-wk high
$16.33
52-wk low
$1.50
EPS
-$3.16
Beta
0.94
Shares outstanding
94.22M
No. of employees
465
Open
$12.87
High
$12.88
Low
$12.07
Mkt. cap
1.19B
Avg. vol.
2.50M
Volume
2.58M
52-wk high
$16.33
52-wk low
$1.50
EPS
-$3.16
Beta
0.94
Shares outstanding
94.22M
No. of employees
465
News stories
From web sources and news partners
About Replimune Group Inc
CEO-
Employees465
Founded2015
HeadquartersWoburn, Massachusetts, United States
SectorBiotechnology
Websitereplimune.com
Analyst ratings
Based on 8 analysts giving stock ratings to REPL in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for REPL in the last 3 months.
Highest
Current $12.60
$24.00 (+90.48%)
Average
$19.14 (+51.90%)
Lowest
$14.00 (+11.11%)
Analyst
Recommendation
Action
Price target
Projected
Date
Evan Seigerman
BMO Capital
Buy
Maintained
$20.00
+58.7%
09/10/2026
Unknown Analyst
Kempen & Co
Buy
Initiated
$19.00
+50.8%
09/10/2026
Anupam Rama
J.P. Morgan
Buy
Reiterated
$21.00
+66.7%
08/26/2026
Roger Song
Jefferies
Buy
Maintained
$24.00
+90.5%
08/17/2026
Robert Driscoll
Wedbush
Buy
Reiterated
$19.00
+50.8%
08/17/2026
Allison Bratzel
Piper Sandler
Buy
Maintained
$14.00
+11.1%
08/07/2026
Daina Graybosch
Leerink Partners
Buy
Upgraded
$17.00
+34.9%
08/03/2026
Li Watsek
Cantor Fitzgerald
Buy
Upgraded
-
-
07/31/2026
Jonathan Chang
Leerink Partners
Hold
Reiterated
-
-
06/02/2026
Robert Burns
H.C. Wainwright
Sell
Downgraded
-
-
04/13/2026
Last report
Aug 14, 2026
Fiscal period
Q1 2027
EPS / Est. (USD)
-$0.72 / -$0.77
+6.25%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
57.28M
52.58M
51.64M
48.77M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
26.64M
18.95M
21.23M
19.18M
Operating expense
83.91M
71.53M
72.87M
67.95M
Total operating expenses
83.91M
71.53M
72.87M
67.95M
Operating income
-83.91M
-71.53M
-72.87M
-67.95M
Other non operating income
-
-
-1.24M
-
EBT including unusual items
-83.10M
-71.24M
-73.46M
-69.77M
EBT excluding unusual items
-83.10M
-71.24M
-73.46M
-69.77M
Income tax expense
-
-311.00K
-240.00K
-
Effective tax rate
-
0.44%
0.33%
-
Other operating expenses
-
-
-
-
Net income
-83.10M
-70.93M
-73.22M
-69.77M
Net profit margin
-
-
-
-
Earnings per share
-0.90
-0.77
-0.76
-0.72
Interest and investment income
3.70M
2.85M
2.37M
1.96M
Interest expense
-2.01M
-1.98M
-2.88M
-3.09M
Net interest expenses
1.69M
866.00K
-508.00K
-1.13M
Depreciation and amortization charges
-
-
-
-
EBITDA
-83.36M
-69.16M
-70.60M
-66.71M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps